Status:
COMPLETED
Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary Disease
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
13-89 years
Brief Summary
To obtain further information on the tolerability and efficacy of Atrovent® 500µg/2ml inhalation solution in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
Eligibility Criteria
Inclusion
- Patients of both genders, older than 40 years,who suffer from chronic obstructive Pulmonary disease
- Only patients who had not been treated with Atrovent® within the last year were to be considered for inclusion
Exclusion
- Contraindication listed in the instructions for use/summary of product characteristics for Atrovent® 500µg/2ml Inhalation Solution
- Patients who exhibited adverse drug reactions
Key Trial Info
Start Date :
February 1 2001
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
477 Patients enrolled
Trial Details
Trial ID
NCT02238197
Start Date
February 1 2001
Last Update
September 12 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.